RECONNECT phase 3 RCT data
A 2019 Obstetrics and Gynecology paper reported two randomised phase 3 trials in 1,202 women, the registrational basis for approval in this indication. Reported in the cited paper.
SourceBack to search
Sexual Health
PT-141
PT-141, known as bremelanotide, is a melanocortin receptor agonist approved as Vyleesi for acquired hypoactive sexual desire disorder in premenopausal women. It acts centrally on arousal pathways rather than on the vascular system like PDE5 inhibitors.
- Lowest cost / mg
- $1.95/mg
- at Amino Club
- Vendors listed
- 57
- In stock
- 60 of 63
- listings
- COA reports
- 45
Vendor listings
Compare PT-141 prices.
Show prices as
56 listings · PT-141
- Amino ClubLowest $/mg
In stock10mgseen 6d ago
In stock3mgseen 6d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 7d ago
In stock10mgseen 3d ago
In stock10mgseen 4d ago
In stock10mgseen 7d ago
In stock10mgseen 7d ago
In stock10mgseen 4d ago
In stock10mgseen 5d ago
In stock10mgseen 6d ago
In stock10mgseen 5d ago
In stock10mgseen 5d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
Overview
What is PT-141?
PT-141, known as bremelanotide, is a melanocortin receptor agonist approved as Vyleesi for acquired hypoactive sexual desire disorder in premenopausal women. It acts centrally on arousal pathways rather than on the vascular system like PDE5 inhibitors.
- Sexual Function
- Libido
- Arousal Support
What the research reports
Reported benefits of PT-141
Outcomes described across the published PT-141 literature and ongoing study. Read each as research context rather than a promised personal result.
- 01
Central arousal mechanism
Activates melanocortin receptors in the brain to influence sexual arousal, working through a different route to PDE5 inhibitors. Reported in research settings.
- 02
Approved HSDD use in women
Registrational trials supported approval for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Reported in research settings.
- 03
Desire and distress outcomes
Phase 3 subgroup analyses reported improved sexual desire and reduced associated distress across the studied populations. Reported in research settings.
- 04
Sustained effect study data
A 52 week open label extension in 684 participants reported sustained improvement with no new safety signals emerging. Described in the research record.
- 05
Male erectile study research
A 2008 randomised trial found intranasal bremelanotide improved erectile function in 33.5 percent of sildenafil resistant men against 8.5 percent on placebo.
Dosage and protocol
How PT-141 is typically studied
Protocols use 1 to 2 mg as needed, 45 minutes to 2 hours before activity, with a maximum of one dose in any 24 hour period. Figures describe study protocols, not a personal regimen.
- Route
- Subcutaneous injection
- Example range
- 1-2 mg
- Frequency
- As needed, one dose daily
- Timing
- 45 minutes to 2 hours before desired effect. Effects last 6 to 12 hours.
Clinical evidence
PT-141 clinical evidence summary
The published PT-141 record, labeled by strength so you can see what is settled and what is still emerging.
Long term safety extension
A 2019 open label extension in 684 participants over 52 weeks reported sustained improvement with no new safety signals identified by the investigators. Reported in the cited paper.
SourceSafety profile review, 2022
A review across the clinical development programme of about 3,500 participants reported mostly mild to moderate events, with nausea leading discontinuation. Reported in the cited paper.
SourceInteractions
How PT-141 pairs with other peptides
- Antihypertensives
- Bremelanotide transiently raises blood pressure, which matters alongside blood pressure medication.
- BPC-157 peptide
- No known interaction. Sexual function and tissue repair act on entirely different target systems.
- Melanotan-2
- Both are melanocortin agonists, so combining duplicates one receptor family and compounds nausea.
- Naltrexone
- Labelling notes reduced exposure to oral naltrexone when the two are taken on the same day.
Questions
Frequently asked questions.
What is PT-141?
PT-141 is a peptide compound used in research settings. It is commonly studied for its role in sexual health, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of PT-141?
PT-141 is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does PT-141 work?
Like other research peptides, PT-141 is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is PT-141 for research use only?
Yes, products like PT-141 are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying PT-141?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
